A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：11
|
作者：
Hertzberg, Mark
Ku, Matthew
Catalani, Olivier
Althaus, Betsy
Simko, Stephen
Gregory, Gareth P.
机构：
[1] Prince Wales Hosp, Sydney, NSW, Australia
[2] St Vincents Hosp, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Monash Univ, Sch Clin Sci Monash Hlth, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS7575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7575
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data
    Budde, Lihua E.
    Olszewski, Adam J.
    Hu, Bei
    Shah, Nikesh
    Batlevi, Connie Lee
    Yin, Shen
    To, Iris
    Wei, Michael C.
    Kallemeijn, Martine
    Orellana-Noia, Victor
    Musick, Lisa
    Shamas, Natasha
    Pal, Navdeep
    Shewade, Ashwini
    Westin, Jason R.
    BLOOD, 2024, 144 : 2373 - 2374
  • [42] Gemcitabine in Combination with Oxaliplatin (GEMOX) As a Salvage Regimen in Patients with Relapsed/Refractory Hodgkin's Lymphoma
    Ozdemir, Evren
    Aslan, Alma
    Turker, Alev
    Barista, Ibrahim
    Kars, Ayse
    BLOOD, 2015, 126 (23)
  • [43] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ghosh, Nilanjan
    Munoz, Javier
    Morgan, David S.
    Dang, Nam H.
    Knapp, Mark
    Delioukina, Maria
    Kingsley, Edwin C.
    Anh Tran
    Ping, Jerry
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Ruan, Jia
    BLOOD, 2016, 128 (22)
  • [44] Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma
    Shen, Qiu-Dan
    Wang, Li
    Zhu, Hua-Yuan
    Liang, Jin-Hua
    Xia, Yi
    Wu, Jia-Zhu
    Fan, Lei
    Li, Jian-Yong
    Xu, Wei
    JOURNAL OF CANCER, 2021, 12 (01): : 163 - 169
  • [45] Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
    Hamadani, Mehdi
    Linhares, Yuliya
    Gandhi, Mitul
    Chung, Michael
    Adamis, Helena
    Ungar, David
    Carlo-Stella, Carmelo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Balari, Anna Sureda
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Chen, Robert W.
    Ansel, Stephen Maxted
    Zinzani, Pier Luigi
    Vacirca, Jeffrey L.
    Lopez-Guillermo, Armando
    Hutchings, Martin
    Jurczak, Wojciech
    Hess, Georg
    Le Gouill, Steven
    Offner, Fritz
    Santoro, Armando
    Salles, Gilles A.
    Stypinski, Darla
    Laird, Douglas
    Pavlov, Dmitri
    Andreola, Giovanna
    Fly, Kolette D.
    Woolfson, Adrian
    Collins, Graham P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Use of gemcitabine, cisplatin and methylprednisolone with or without rituximab in relapsed and refractory patients with diffuse large B-cell lymphoma
    Sirohi, B
    Cunningham, D
    Norman, A
    Trumper, M
    Prior, Y
    Last, K
    Chong, G
    Horwich, A
    Wotherspoon, A
    BONE MARROW TRANSPLANTATION, 2006, 37 : S240 - S240
  • [50] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
12345